MA46255A - Vaccins anticancéreux - Google Patents

Vaccins anticancéreux

Info

Publication number
MA46255A
MA46255A MA046255A MA46255A MA46255A MA 46255 A MA46255 A MA 46255A MA 046255 A MA046255 A MA 046255A MA 46255 A MA46255 A MA 46255A MA 46255 A MA46255 A MA 46255A
Authority
MA
Morocco
Prior art keywords
cancer vaccines
vaccines
cancer
Prior art date
Application number
MA046255A
Other languages
English (en)
Inventor
Giuseppe Ciaramella
Eric Yi-Chun Huang
Nicholas Valiante
Tal Zaks
Original Assignee
Modernatx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modernatx Inc filed Critical Modernatx Inc
Publication of MA46255A publication Critical patent/MA46255A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001114—CD74, Ii, MHC class II invariant chain or MHC class II gamma chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Cell Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MA046255A 2015-10-22 2016-10-21 Vaccins anticancéreux MA46255A (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562245031P 2015-10-22 2015-10-22
US201562245129P 2015-10-22 2015-10-22
US201562247317P 2015-10-28 2015-10-28
US201562247472P 2015-10-28 2015-10-28
US201662368810P 2016-07-29 2016-07-29

Publications (1)

Publication Number Publication Date
MA46255A true MA46255A (fr) 2019-07-31

Family

ID=58558197

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046255A MA46255A (fr) 2015-10-22 2016-10-21 Vaccins anticancéreux

Country Status (8)

Country Link
US (1) US20180318409A1 (fr)
EP (1) EP3364949A4 (fr)
JP (2) JP2018532777A (fr)
CN (2) CN114404581A (fr)
AU (2) AU2016341309A1 (fr)
CA (1) CA3003090A1 (fr)
MA (1) MA46255A (fr)
WO (1) WO2017070618A1 (fr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
BR112016024644A2 (pt) 2014-04-23 2017-10-10 Modernatx Inc vacinas de ácido nucleico
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
ES2937963T3 (es) 2015-07-21 2023-04-03 Modernatx Inc Vacunas de enfermedad infecciosa
US11564893B2 (en) 2015-08-17 2023-01-31 Modernatx, Inc. Methods for preparing particles and related compositions
TW201729838A (zh) 2015-10-22 2017-09-01 現代公司 用於水痘帶狀疱疹病毒 (vzv)之核酸疫苗
MA45209A (fr) 2015-10-22 2019-04-17 Modernatx Inc Vaccins contre les maladies sexuellement transmissibles
EP3364950A4 (fr) 2015-10-22 2019-10-23 ModernaTX, Inc. Vaccins contre des maladies tropicales
JP6921833B2 (ja) 2015-10-22 2021-08-18 モデルナティーエックス， インコーポレイテッド ヒトサイトメガロウイルスワクチン
MA47016A (fr) 2015-10-22 2018-08-29 Modernatx Inc Vaccins contre les virus respiratoires
JP7080172B2 (ja) 2015-12-10 2022-06-03 モデルナティエックス インコーポレイテッド 治療薬の送達のための組成物及び方法
US10465190B1 (en) 2015-12-23 2019-11-05 Modernatx, Inc. In vitro transcription methods and constructs
IL263079B2 (en) 2016-05-18 2024-05-01 Modernatx Inc Relaxin-encoding polynucleotides
CN109937253B (zh) 2016-09-14 2023-06-30 摩登纳特斯有限公司 高纯度rna组合物及其制备方法
CA3041307A1 (fr) 2016-10-21 2018-04-26 Giuseppe Ciaramella Vaccin contre le cytomegalovirus humain
US10925958B2 (en) 2016-11-11 2021-02-23 Modernatx, Inc. Influenza vaccine
EP3551193A4 (fr) 2016-12-08 2020-08-19 Modernatx, Inc. Vaccins à acide nucléique contre des virus respiratoires
US11384352B2 (en) 2016-12-13 2022-07-12 Modernatx, Inc. RNA affinity purification
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
RU2768829C2 (ru) * 2017-02-01 2022-03-24 МОДЕРНАТиЭкс, ИНК. Противораковые рнк-вакцины
EP3582790A4 (fr) 2017-02-16 2020-11-25 ModernaTX, Inc. Compositions immunogènes très puissantes
EP3595713A4 (fr) 2017-03-15 2021-01-13 ModernaTX, Inc. Vaccin contre le virus respiratoire syncytial
US11576961B2 (en) 2017-03-15 2023-02-14 Modernatx, Inc. Broad spectrum influenza virus vaccine
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
US11045540B2 (en) 2017-03-15 2021-06-29 Modernatx, Inc. Varicella zoster virus (VZV) vaccine
MA47790A (fr) 2017-03-17 2021-05-05 Modernatx Inc Vaccins à base d'arn contre des maladies zoonotiques
WO2018187590A1 (fr) 2017-04-05 2018-10-11 Modernatx, Inc. Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée
MA49421A (fr) 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
WO2019006371A1 (fr) * 2017-06-30 2019-01-03 City Of Hope Compositions et procédés de modulation de l'activité macrophage
EP3668971B8 (fr) 2017-08-18 2024-05-29 ModernaTX, Inc. Variants d'arn polymérase
WO2019036683A1 (fr) 2017-08-18 2019-02-21 Modernatx, Inc. Procédés analytiques par hplc
MA49922A (fr) 2017-08-18 2021-06-02 Modernatx Inc Procédés pour analyse par clhp
WO2019046809A1 (fr) 2017-08-31 2019-03-07 Modernatx, Inc. Procédés de fabrication de nanoparticules lipidiques
EP3681514A4 (fr) 2017-09-14 2021-07-14 ModernaTX, Inc. Vaccins à arn contre le virus zika
GB2574785A (en) 2017-09-15 2019-12-25 Jan Loetvall Method and system for identifying membrane proteins on extracellular vesicles
US20210052646A1 (en) * 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Nucleic-acid containing lipid nano-particle and use thereof
EP3746090A4 (fr) 2018-01-29 2021-11-17 ModernaTX, Inc. Vaccins à base d'arn contre le vrs
EP3752177A1 (fr) * 2018-02-12 2020-12-23 BioNTech RNA Pharmaceuticals GmbH Traitement à l'aide d'arn codant une cytokine
JP2021529750A (ja) * 2018-06-27 2021-11-04 モデルナティーエックス， インコーポレイテッド 個別化がんワクチンエピトープの選択
WO2020020444A1 (fr) * 2018-07-24 2020-01-30 Biontech Rna Pharmaceuticals Gmbh Vaccins individualisés pour le cancer
WO2020061457A1 (fr) * 2018-09-20 2020-03-26 Modernatx, Inc. Préparation de nanoparticules lipidiques et leurs méthodes d'administration
JP2022512578A (ja) 2018-10-09 2022-02-07 ザ ユニヴァーシティ オブ ブリティッシュ コロンビア 有機溶媒不含かつ劣化剤不含のトランスフェクション・コンピテント・ベシクルを含む組成物及びシステム並びにそれらに関連する方法
EP3873499A4 (fr) * 2018-10-29 2022-11-02 Health Research, Inc. Cibles immunothérapeutiques spécifiques du cancer générées par traitement médicamenteux chimiothérapeutique
JP2022506839A (ja) * 2018-11-07 2022-01-17 モデルナティエックス インコーポレイテッド Ｒｎａがんワクチン
CN113424264B (zh) * 2018-11-15 2024-04-12 Nouscom股份公司 用于生成个性化癌症疫苗的癌症突变选择
CN113677328A (zh) * 2019-01-09 2021-11-19 埃克索丘尔生物科学股份有限公司 细菌来源的囊泡及其用途
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
US20220096539A1 (en) * 2019-01-18 2022-03-31 University Of Georgia Research Foundation, Inc. Salt nanoparticles and compositions and methods of use thereof
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
BR112022001947A2 (pt) * 2019-08-14 2022-09-20 Curevac Ag Combinações e composições de rna com propriedades imunoestimuladoras reduzidas
AU2020385683A1 (en) 2019-11-18 2022-06-30 Janssen Biotech, Inc. Vaccines based on mutant CALR and JAK2 and their uses
WO2021113500A2 (fr) * 2019-12-03 2021-06-10 Board Of Regents, The University Of Texas System Polythérapies pour le traitement du cancer
WO2021168290A1 (fr) * 2020-02-19 2021-08-26 University Of Florida Research Foundation, Incorporated Nanoparticules d'arn multilamellaires et méthodes de sensibilisation de tumeurs au traitement par des inhibiteurs de points de contrôle immunitaires
EP3901261A1 (fr) 2020-04-22 2021-10-27 BioNTech RNA Pharmaceuticals GmbH Vaccin contre le coronavirus
CN115803333A (zh) 2020-07-02 2023-03-14 生命技术公司 三核苷酸帽类似物、其制备和用途
CN111773381A (zh) * 2020-07-06 2020-10-16 贵阳市第二人民医院 一种靶向tem-1基因疫苗及其构建与应用
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
WO2022120560A1 (fr) * 2020-12-08 2022-06-16 深圳市瑞吉生物科技有限公司 Immunosuppresseur sous forme posologique d'arnm et son application dans la préparation d'un médicament pour le traitement de tumeurs
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
KR20240042414A (ko) * 2021-07-29 2024-04-02 비온테크 에스이 흑색종의 치료용 조성물 및 방법
AU2022336209A1 (en) 2021-09-03 2024-01-18 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
WO2023069625A1 (fr) * 2021-10-20 2023-04-27 Modernatx, Inc. Solutions de substitution de produit médicamenteux
WO2023073228A1 (fr) 2021-10-29 2023-05-04 CureVac SE Arn circulaire amélioré pour exprimer des protéines thérapeutiques
WO2023144330A1 (fr) 2022-01-28 2023-08-03 CureVac SE Inhibiteurs de facteurs de transcription codés par un acide nucleique
WO2023194537A1 (fr) * 2022-04-08 2023-10-12 Glaxosmithkline Intellectual Property Development Limited Nouveaux procédés de production de polynucléotides comprenant des oligonucléotides
WO2023227608A1 (fr) 2022-05-25 2023-11-30 Glaxosmithkline Biologicals Sa Vaccin à base d'acide nucléique codant pour un polypeptide antigénique fimh d'escherichia coli
WO2024002985A1 (fr) 2022-06-26 2024-01-04 BioNTech SE Vaccin contre le coronavirus
WO2024004159A1 (fr) * 2022-06-30 2024-01-04 Ｅｐｓ創薬株式会社 Composition de vaccin pour une administration sublinguale
WO2024089638A1 (fr) 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Vaccin à base d'acide nucléique
CN116083463B (zh) * 2022-12-16 2024-06-21 四川大学华西医院 一种用于增强免疫疗法效果的mRNA及其在制备mRNA疫苗中的用途
CN115671045B (zh) * 2022-12-30 2023-04-07 华南理工大学 非肝靶向的核酸纳米制剂及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6432925B1 (en) * 1998-04-16 2002-08-13 John Wayne Cancer Institute RNA cancer vaccine and methods for its use
CN1129667C (zh) * 2001-12-26 2003-12-03 中国人民解放军第二军医大学 治疗肿瘤的自体免疫细胞及其制备方法
US20040175813A1 (en) * 2002-05-24 2004-09-09 Kimberly Kline Mutant P53 proteins and uses thereof
CN103180730B (zh) * 2010-05-14 2016-03-02 综合医院公司 鉴定肿瘤特异性新抗原的组合物和方法
CN105999250B (zh) * 2011-05-24 2020-03-10 生物技术Rna制药有限公司 用于癌症的个体化疫苗
JP6120839B2 (ja) * 2011-07-06 2017-04-26 ノバルティス アーゲー カチオン性水中油型エマルジョン
KR20140102759A (ko) * 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
WO2013143555A1 (fr) * 2012-03-26 2013-10-03 Biontech Ag Formulation d'arn pour immunothérapie
EP2833892A4 (fr) * 2012-04-02 2016-07-20 Moderna Therapeutics Inc Polynucléotides modifiés destinés à la production de protéines et de peptides associés à l'oncologie
WO2013151666A2 (fr) * 2012-04-02 2013-10-10 modeRNA Therapeutics Polynucléotides modifiés destinés à la production de produits biologiques et de protéines associées à une maladie humaine
WO2014082729A1 (fr) * 2012-11-28 2014-06-05 Biontech Ag Vaccins individualisés contre le cancer
EP3757570B1 (fr) * 2013-03-15 2023-10-11 Translate Bio, Inc. Amélioration synergique de l'administration d'acides nucléiques par l'intermédiaire de formulations mélangées
EA201690576A1 (ru) * 2013-10-22 2016-10-31 Шир Хьюман Дженетик Терапис, Инк. Липидные композиции для доставки матричной рнк
WO2015130584A2 (fr) * 2014-02-25 2015-09-03 Merck Sharp & Dohme Corp. Adjuvants de vaccins sous forme de nanoparticules lipidiques et systèmes d'administration d'antigènes
ES2834556T3 (es) * 2014-06-25 2021-06-17 Acuitas Therapeutics Inc Lípidos y formulaciones de nanopartículas lipídicas novedosos para la entrega de ácidos nucleicos
WO2017020026A1 (fr) * 2015-07-30 2017-02-02 Modernatx, Inc. Arn épitopes peptidiques concatémériques

Also Published As

Publication number Publication date
CN114404581A (zh) 2022-04-29
EP3364949A1 (fr) 2018-08-29
CA3003090A1 (fr) 2017-04-27
JP2023024669A (ja) 2023-02-16
AU2024200425A1 (en) 2024-02-15
CN108430456A (zh) 2018-08-21
AU2016341309A1 (en) 2018-06-07
US20180318409A1 (en) 2018-11-08
EP3364949A4 (fr) 2019-07-31
CN108430456B (zh) 2022-01-18
WO2017070618A1 (fr) 2017-04-27
JP2018532777A (ja) 2018-11-08

Similar Documents

Publication Publication Date Title
MA46255A (fr) Vaccins anticancéreux
DK3393510T3 (da) Zikavirusvaccine
MA52645A (fr) Vaccins contre le virus respiratoire
DK3218386T3 (da) Modulatorisk polynukleotid
MA46378A (fr) Vaccins hpv16 thérapeutiques
GB201518684D0 (en) Vaccine
GB201410971D0 (en) Vaccine
DK3119885T3 (da) Antistof-fynomer-konjugater
DK3089741T3 (da) Farmaceutiske sammensætninger omfattende azd9291
MA41107A (fr) Compositions anti-cancéreuses
PL3185899T3 (pl) Wzmocniona szczepionka wektorowa-hvt przeciwko nd-ibd
DK3198111T3 (da) Forbedret prop
DK3171700T3 (da) Infusionsanlæg
DK3199161T3 (da) Farmaceutisk præparat
DK3129007T3 (da) Vaccinesammensætninger
GB201522132D0 (en) Vaccine
DK3228706T3 (da) Coekspressionsplasmid
DK3205661T3 (da) Hsp70-afledt immunitetsinducerende peptid
HUE064499T2 (hu) Hiszton rákellenes vakcinák
GB201616904D0 (en) Vaccine
DK3405212T3 (da) Cancervacciner
DE112016001834A5 (de) Kanüle
LT3188755T (lt) Vakcina
DK3155004T3 (da) Vaccine til immunkompromitterede værter
DK3089740T3 (da) Farmaceutisk sammensætning